

## REFERENCES

1. Seidel MG, Planitzer CB, Kreil TR, Förster-Waldl E. Tick-borne encephalitis vaccine as additional alternative neoantigen for the clinical immunologist's toolbox. *J Allergy Clin Immunol* 2013;131:617.
2. Orange JS, Ballou M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. *J Allergy Clin Immunol* 2012;130:S1-24.
3. Seidel MG, Grohmann E, Sadeghi K, Pollak A, Heitger A, Förster-Waldl E. Vaccination against tick-borne encephalitis virus tests specific IgG production ability in patients under immunoglobulin substitution therapy. *Vaccine* 2010;28:6621-6.
4. Mansfield KL, Johnson N, Phipps LP, Stephenson JR, Fooks AR, Solomon T. Tick-borne encephalitis virus—a review of an emerging zoonosis. *J Gen Virol* 2009;90:1781-94.

Available online December 28, 2012.  
<http://dx.doi.org/10.1016/j.jaci.2012.11.030>

**Corrections**

With regard to the May 2012 article entitled “Influence of maternal asthma on the cause and severity of infant acute respiratory tract infections” (*J Allergy Clin Immunol* 2012;129:1236-42), the third sentence under the Study design and setting heading inaccurately describes the cohort. The sentence should read “The TCRI is a prospective cohort of 673 term ( $\geq 37$  weeks) infants with birth weight  $\geq 2275$  g and their mothers designed to investigate the association of characteristics of infant viral ARIs, such as severity and cause, and familial atopic predisposition on the development of early childhood asthma and atopy.<sup>23</sup>”

With regard to the November 2012 article entitled “Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs” (*J Allergy Clin Immunol* 2012;130:1049-62), three contributors who were listed as reviewers of the paper should have been listed as authors instead. Those individuals are P. G. Burney, MD, S. L. Johnston, MD, and J. O. Warner, MD.

Drs Burney, Johnston, and Warner disclose the following potential conflicts of interest: P. G. Burney has received grants from MRC and the Wellcome Trust and has received travel or meeting expenses from INSERM; in addition, his institution has received fees from GSK for work he has done on monitoring the quality of data in a project not related to this publication. S. L. Johnston has consulted for Centocor, Sanofi Pasteur, Synairgen, GSK, Chiesi, Boehringer Ingelheim, Grünenthal, and Novartis; has stock or stock options in Synairgen; and has contributed to patents owned by his institution on topics outside of the scope of the current article. J. O. Warner has received grants from Aironette, Danone, Lincoln Medical, and Allergy Therapeutics; has served on scientific advisory boards for Danone, Airsonette, and Mead Johnson; has received speaker fees from Merck, Novartis, and Allergy Therapeutics; and has received payment for development of educational materials from UCB Pharma.